185 related articles for article (PubMed ID: 28187497)
1. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Kajubi R; Huang L; Jagannathan P; Chamankhah N; Were M; Ruel T; Koss CA; Kakuru A; Mwebaza N; Kamya M; Havlir D; Dorsey G; Rosenthal PJ; Aweeka FT
Clin Pharmacol Ther; 2017 Sep; 102(3):520-528. PubMed ID: 28187497
[TBL] [Abstract][Full Text] [Related]
2. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Wallender E; Vucicevic K; Jagannathan P; Huang L; Natureeba P; Kakuru A; Muhindo M; Nakalembe M; Havlir D; Kamya M; Aweeka F; Dorsey G; Rosenthal PJ; Savic RM
J Infect Dis; 2018 Mar; 217(6):964-972. PubMed ID: 29272443
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
[TBL] [Abstract][Full Text] [Related]
4. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.
Tarning J; Rijken MJ; McGready R; Phyo AP; Hanpithakpong W; Day NP; White NJ; Nosten F; Lindegardh N
Antimicrob Agents Chemother; 2012 Apr; 56(4):1997-2007. PubMed ID: 22252822
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.
Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784846
[TBL] [Abstract][Full Text] [Related]
7. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
Hong H; Aslam-Mir U; Kajubi R; Wallender E; Mwebaza N; Dorsey G; Rosenthal PJ; Aweeka FT; Huang L
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0142722. PubMed ID: 36916944
[TBL] [Abstract][Full Text] [Related]
9. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
Hughes E; Imperial M; Wallender E; Kajubi R; Huang L; Jagannathan P; Zhang N; Kakuru A; Natureeba P; Mwima MW; Muhindo M; Mwebaza N; Clark TD; Opira B; Nakalembe M; Havlir D; Kamya M; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020153
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Kakuru A; Jagannathan P; Muhindo MK; Natureeba P; Awori P; Nakalembe M; Opira B; Olwoch P; Ategeka J; Nayebare P; Clark TD; Feeney ME; Charlebois ED; Rizzuto G; Muehlenbachs A; Havlir DV; Kamya MR; Dorsey G
N Engl J Med; 2016 Mar; 374(10):928-39. PubMed ID: 26962728
[TBL] [Abstract][Full Text] [Related]
11. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
[TBL] [Abstract][Full Text] [Related]
12. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.
Whalen ME; Kajubi R; Chamankhah N; Huang L; Orukan F; Wallender E; Kamya MR; Dorsey G; Jagannathan P; Rosenthal PJ; Mwebaza N; Aweeka FT
Clin Pharmacol Ther; 2019 Dec; 106(6):1310-1318. PubMed ID: 31173649
[TBL] [Abstract][Full Text] [Related]
13. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Kajubi R; Ochieng T; Kakuru A; Jagannathan P; Nakalembe M; Ruel T; Opira B; Ochokoru H; Ategeka J; Nayebare P; Clark TD; Havlir DV; Kamya MR; Dorsey G
Lancet; 2019 Apr; 393(10179):1428-1439. PubMed ID: 30910321
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.
Rijken MJ; McGready R; Phyo AP; Lindegardh N; Tarning J; Laochan N; Than HH; Mu O; Win AK; Singhasivanon P; White N; Nosten F
Antimicrob Agents Chemother; 2011 Dec; 55(12):5500-6. PubMed ID: 21947392
[TBL] [Abstract][Full Text] [Related]
15. Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
Banda CG; Nkosi D; Allen E; Workman L; Madanitsa M; Chirwa M; Kapulula M; Muyaya S; Munharo S; Tarning J; Phiri KS; Mwapasa V; Ter Kuile FO; Maartens G; Barnes KI
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0058422. PubMed ID: 36374096
[TBL] [Abstract][Full Text] [Related]
16. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial.
Sevene E; Banda CG; Mukaka M; Maculuve S; Macuacua S; Vala A; Piqueras M; Kalilani-Phiri L; Mallewa J; Terlouw DJ; Khoo SH; Lalloo DG; Mwapasa V
Malar J; 2019 Aug; 18(1):277. PubMed ID: 31429785
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Benjamin JM; Moore BR; Salman S; Page-Sharp M; Tawat S; Yadi G; Lorry L; Siba PM; Batty KT; Robinson LJ; Mueller I; Davis TM
Antimicrob Agents Chemother; 2015 Jul; 59(7):4260-71. PubMed ID: 25963981
[TBL] [Abstract][Full Text] [Related]
19. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.
Hoglund RM; Adam I; Hanpithakpong W; Ashton M; Lindegardh N; Day NP; White NJ; Nosten F; Tarning J
Malar J; 2012 Nov; 11():398. PubMed ID: 23190801
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data.
Fernandes S; Were V; Gutman J; Dorsey G; Kakuru A; Desai M; Kariuki S; Kamya MR; Ter Kuile FO; Hanson K
Lancet Glob Health; 2020 Dec; 8(12):e1512-e1523. PubMed ID: 33137287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]